Mustang Bio, Inc. MBIO
Mustang Bio, Inc. (Nasdaq: MBIO) is an oncology drug developer. Its lead program, MB-109 (combination of MB-101 CAR T and MB-108 oncolytic virus), is in Phase 1 for IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma. Its next catalyst on record is MB-109: Potential initiation of investigator-sponsored single-institution trial at COH (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: MB-109 — Potential initiation of investigator-sponsored single-institution trial at COH (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| MB-109 (combination of MB-101 and MB-108) | IL13Rα2+ relapsed or refractory glioblastoma and high-grade astrocytoma | cell therapy | Phase 1 |
| MB-101 | Malignant brain tumors (IL13Rα2-targeted) | cell therapy | Phase 1 |
| MB-108 | High-grade malignant brain tumors | gene therapy | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.